Addressing Life-Threatening Diseases with Significant Unmet Need & Limited Treatment Options

Transforming the way cancer is treated

 

 
 

Transforming the way cancer is treated

 

  • The human immune system can tell the difference between normal cells in the body and those it sees as “foreign”, which allows it to focus an attack on the foreign cells while leaving the normal cells alone.
  • To do this, our immune systems use “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response.
  • Cancer cells can find ways to use these checkpoints to avoid being attacked by the immune system.
  • Kairos Pharma is developing small molecules that target these central checkpoints to induce the immune system into attacking cancer cells.
  • In addition, Kairos is developing an activated T cell therapy that transforms a patient’s T cells into killer activated T cells against cancerous stem cells.

Next-Generation Science to Address Life-Threatening Diseases

KROS-101 Systemic immune modulator

Stage: Pre-IND Studies For 2022 Submission / Phase 1 Clinical Trial 2022

Small molecule agonist of GITR developed to address immunosuppressive activity of solid cancers. KROS-101 is designed to deplete regulatory T cells (Tregs) and activate effector T cells and thereby augment the antitumor immune response.

KROS-102 GITR antagonist

Stage: Preclinical Development

A GITR antagonist that increases the inhibitory regulatory T cell (Treg) functions while hampering T effector cell numbers and function. KROS-102 has been shown to decrease T effector cells and increase Treg cells in a dose dependent fashion.

KROS-201 Activated T cell technology

Stage: IND enabling Studies/Phase 1 Clinical Trial 2022

Autologous T cells are primed with dendritic cells with antigens targeting glioblastoma cancer stem cells. Cytotoxic and helper T cells are generated ex vivo and infused into patients with recurrent glioblastoma.

KROS-301 Tumor targeting small molecule and checkpoint inhibitor

Stage: Preclinical Development

A small molecule inhibitor with two distinct mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway. NF-KB is a key component for cancer growth and drug resistance.

KROS-301 kills tumor cells in RelA/p65 biomarker positive solid tumors.

KROS-401 Tumor microenvironment immune modulator

Stage: Preclinical Development

Cyclic peptide inhibitor of IL4/IL13 cytokine immune receptors for triple negative breast cancer and in addition, it increases anti-tumor response in conjunction with radiation therapy.

ENV-105 Antibody targeting Endoglin for resistance

Stage: Phase 1 + 2 in 2022

  • Antibody targeting Endoglin to reverse therapeutic resistance.
  • Androgen target therapy resistance (prostate cancer) Phase 2 Clinical Trial in 2022.
  • EGFR antagonist resistance (lung cancer) Phase 1 Clinical Trial IND submission in 2022.

ENV-205 Antibody targeting mt DNA

Stage: Preclinical Development

Antibody targeting mitochondrial DNA to reverse chemotherapy resistance (prostate, colon, and pancreatic cancer).

Next-Generation Science to Address Life-Threatening Diseases

KROS-101 Systemic immune modulator

Stage: Pre-IND Studies For 2022 Submission / Phase 1 Clinical Trial 2022

Small molecule agonist of GITR developed to address immunosuppressive activity of solid cancers. KROS-101 is designed to deplete regulatory T cells (Tregs) and activate effector T cells and thereby augment the antitumor immune response.

KROS-102 GITR antagonist

Stage: Preclinical Development

A GITR antagonist that increases the inhibitory regulatory T cell (Treg) functions while hampering T effector cell numbers and function. KROS-102 has been shown to decrease T effector cells and increase Treg cells in a dose dependent fashion.

KROS-201 Activated T cell technology

Stage: IND enabling Studies/Phase 1 Clinical Trial 2022

Autologous T cells are primed with dendritic cells with antigens targeting glioblastoma cancer stem cells. Cytotoxic and helper T cells are generated ex vivo and infused into patients with recurrent glioblastoma.

KROS-301 Tumor targeting small molecule and checkpoint inhibitor

Stage: Preclinical Development

A small molecule inhibitor with two distinct mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway. NF-KB is a key component for cancer growth and drug resistance.

KROS-301 kills tumor cells in RelA/p65 biomarker positive solid tumors.

KROS-401 Tumor microenvironment immune modulator

Stage: Preclinical Development

Cyclic peptide inhibitor of IL4/IL13 cytokine immune receptors for triple negative breast cancer and in addition, it increases anti-tumor response in conjunction with radiation therapy.

ENV-105 Antibody targeting Endoglin for resistance

Stage: Phase 1 + 2 in 2022

  • Antibody targeting Endoglin to reverse therapeutic resistance.
  • Androgen target therapy resistance (prostate cancer) Phase 2 Clinical Trial in 2022.
  • EGFR antagonist resistance (lung cancer) Phase 1 Clinical Trial IND submission in 2022.

ENV-205 Antibody targeting mt DNA

Stage: Preclinical Development

Antibody targeting mitochondrial DNA to reverse chemotherapy resistance (prostate, colon, and pancreatic cancer).

Strong Intellectual Property Foundation

PCT/US2016/035318

METHODS AND USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB

PCT/US2015/050906

COMPOSITIONS AND METHODS FOR TREATING FIBROSIS

PCT/US2019/045478

COMPOSITIONS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES

PCT/US2020/045570

METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY

PCT/US2017/037558

SENSITIZATION OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM

Strong Intellectual Property Foundation

PCT/US2016/035318

METHODS AND USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB

PCT/US2015/050906

COMPOSITIONS AND METHODS FOR TREATING FIBROSIS

PCT/US2019/045478

COMPOSITIONS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES

PCT/US2020/045570

METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY

PCT/US2017/037558

SENSITIZATION OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM

MILESTONES

  • GITR and Other Immune Agents Developed by Yu Lab & Collaborators at Cedars-Sinai Medical Center
  • Kairos Pharma Spun-off From Cedars-Sinai Medical Center on April, 2016
  • GITR Preclinical & Biodistribution / Toxicology Studies
  • Enviro Therapeutics Completes Phase I/II ENV105 Prostate Cancer Clinical Trial
  • Enviro Therapeutics IND for Phase II ENV105 Clinical Trials
  • Strategic & Corporate Development Advisory Board
  • Planned Launch of ENV105 Prostate Cancer Phase II, ENV105 Non-Small Cell Lung Cancer Phase I, KROS-201 Glioblastoma Phase I

MILESTONES

2015

  • GITR and Other Immune Agents Developed by Yu Lab & Collaborators at Cedars-Sinai Medical Center.

2016

  • Kairos Pharma Spun-off From Cedars-Sinai Medical Center on April, 2016.

2017-2021

  • GITR Preclinical & Biodistribution / Toxicology Studies
  • Enviro Therapeutics Completes Phase I/II ENV105 Prostate Cancer Clinical Trial
  • Enviro Therapeutics IND for Phase II ENV105 Clinical Trials

2022+

  • Strategic & Corporate Development Advisory Board
  • Planned Launch of ENV105 Prostate Cancer Phase II, ENV105 Non-Small Cell Lung Cancer Phase I, KROS-201 Glioblastoma Phase I

Stay up to date with our latest global news, events and more.